Supporting Down Syndrome Cognitive Research
Research Down Syndrome (RDS) is a leading source of private funding for Down syndrome related cognitive research. RDS supports and funds Down syndrome cognitive research conducted at preeminent research institutions including:
Johns Hopkins University
University of Arizona
University of California, San Diego
University of Texas, Austin
VA Palo Alto Health Care System
Empower the Extraordinary
Over the last 30 years, the average life expectancy of individuals with Down syndrome increased from age 20 to 60+. Despite the increased availability of educational, social and occupational opportunities, the cognitive impairment associated with Down syndrome precludes independent living for the majority of those with Down syndrome. There remains a large unmet medical need for pharmacologic therapies to address not only the learning and behavioral challenges associated with Down syndrome, but also the increased likelihood for Alzheimer’s disease. Historically, little or no funding was directed toward Down syndrome cognitive research and, consequently, few advances were possible in this field.
This is changing.
Research Down Syndrome is committed to supporting the identification of the causes of the intellectual impairments associated with Down syndrome and to facilitating the development of pharmacological therapies to improve memory, learning and communication in persons with Down syndrome. Remarkable progress has already been made over a very short time. In fact, two human clinical trials have already begun, and a third trial has been approved to begin. These advances have occurred less than a decade after the support of private foundations stimulated the progress of Down syndrome cognitive research. Your support will help translate these research initiatives into a reality.